110 related articles for article (PubMed ID: 25103664)
1. Intravitreal dexamethasone implant (Ozurdex) and photodynamic therapy for vasoproliferative retinal tumours.
Cebeci Z; Oray M; Tuncer S; Tugal Tutkun I; Kir N
Can J Ophthalmol; 2014 Aug; 49(4):e83-4. PubMed ID: 25103664
[No Abstract] [Full Text] [Related]
2. Vasoproliferative tumors of the retina secondary to ocular toxocariasis.
Mori K; Ohta K; Murata T
Can J Ophthalmol; 2007 Oct; 42(5):758-9. PubMed ID: 17891207
[No Abstract] [Full Text] [Related]
3. Update on the management of vasoproliferative tumour.
Temblador-Barba I; Delgado-Alonso EM; Toribio-García M; Martínez-Campillo L; Molina-Leyva I; Martínez-Jiménez M
Arch Soc Esp Oftalmol (Engl Ed); 2018 Jul; 93(7):350-353. PubMed ID: 29459169
[TBL] [Abstract][Full Text] [Related]
4. [Vasoproliferative retinal tumors].
Windisch-Furrer R; Kurz-Levin MM; Sutter FK; Reineke T; Helbig H
Klin Monbl Augenheilkd; 2007 Apr; 224(4):364-6. PubMed ID: 17458816
[TBL] [Abstract][Full Text] [Related]
5. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema.
Callanan DG; Gupta S; Boyer DS; Ciulla TA; Singer MA; Kuppermann BD; Liu CC; Li XY; Hollander DA; Schiffman RM; Whitcup SM;
Ophthalmology; 2013 Sep; 120(9):1843-51. PubMed ID: 23706947
[TBL] [Abstract][Full Text] [Related]
6. Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion.
Bakri SJ; Omar AF
J Ocul Pharmacol Ther; 2012 Oct; 28(5):547-9. PubMed ID: 22537269
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy with verteporfin for vasoproliferative tumour of the retina.
Chan RP; Lai TY
Acta Ophthalmol; 2010 Sep; 88(6):711-2. PubMed ID: 21089226
[No Abstract] [Full Text] [Related]
8. Intravitreal ranibizumab, intravitreal ranibizumab with photodynamic therapy (PDT), and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation.
Sahu AK; Narayanan R
Retina; 2010 Jun; 30(6):981; author reply 981. PubMed ID: 20531149
[No Abstract] [Full Text] [Related]
9. Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion.
Pichi F; Specchia C; Vitale L; Lembo A; Morara M; Veronese C; Ciardella AP; Nucci P
Am J Ophthalmol; 2014 Mar; 157(3):607-15.e1. PubMed ID: 24528934
[TBL] [Abstract][Full Text] [Related]
10. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
Saito M; Shiragami C; Shiraga F; Kano M; Iida T
Am J Ophthalmol; 2010 Mar; 149(3):472-81.e1. PubMed ID: 20053392
[TBL] [Abstract][Full Text] [Related]
11. Effect of combination therapy with bevacizumab and dexamethasone intravitreal implant in patients with retinal vein occlusion.
Singer MA; Bell DJ; Woods P; Pollard J; Boord T; Herro A; Porbandarwalla S
Retina; 2012 Jul; 32(7):1289-94. PubMed ID: 22466480
[TBL] [Abstract][Full Text] [Related]
12. Micropulsed laser photocoagulation and intravitreal triamcinolone acetonide injection for the treatment of retinal angiomatous proliferation.
Roth DB; Scott IU; Gloth JM; Green SN; Yarian DL; Wheatley M
Retina; 2007; 27(9):1201-4. PubMed ID: 18046225
[TBL] [Abstract][Full Text] [Related]
13. Macular hole after injection of dexamethasone intravitreal implant for macular oedema due to central retinal vein occlusion.
De Benedetto U; Battaglia Parodi M; Knutsson KA; Lattanzio R; Bandello F; Iacono P
Acta Ophthalmol; 2013 Feb; 91(1):e75-7. PubMed ID: 22863290
[No Abstract] [Full Text] [Related]
14. Acute retinal necrosis and ocular neovascularization caused by cytomegalovirus following intravitreal dexamethasone implant (Ozurdex
Thrane AS; Hove M; Kjersem B; Krohn J
Acta Ophthalmol; 2016 Dec; 94(8):e813-e814. PubMed ID: 27274005
[No Abstract] [Full Text] [Related]
15. Choroidal neovascularization and chorioretinal anastomoses following laser treatment of a secondary vasoproliferative tumor.
Chen CY; Engelbert M; Freund KB; Shields CL; Barile G
JAMA Ophthalmol; 2014 Dec; 132(12):1488-90. PubMed ID: 25188825
[No Abstract] [Full Text] [Related]
16. Retinal vasoproliferative tumor.
Marback EF; Guerra RL; Maia Junior Ode O; Marback RL
Arq Bras Oftalmol; 2013; 76(3):200-3. PubMed ID: 23929086
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone intravitreal implant during phacoemulsification.
Agarwal A; Gupta V; Ram J; Gupta A
Ophthalmology; 2013 Jan; 120(1):211, 211.e1-5. PubMed ID: 23283186
[No Abstract] [Full Text] [Related]
18. The Sustained-Release Dexamethasone Implant: Expanding Indications in Vitreoretinal Disease.
Kapoor KG; Wagner MG; Wagner AL
Semin Ophthalmol; 2015; 30(5-6):475-81. PubMed ID: 24654698
[TBL] [Abstract][Full Text] [Related]
19. Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function.
Querques G; Lattanzio R; Querques L; Triolo G; Cascavilla ML; Cavallero E; Del Turco C; Casalino G; Bandello F
Retina; 2014 Feb; 34(2):330-41. PubMed ID: 23945638
[TBL] [Abstract][Full Text] [Related]
20. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency.
Zarranz-Ventura J; Carreño E; Johnston RL; Mohammed Q; Ross AH; Barker C; Fonollosa A; Artaraz J; Pelegrin L; Adan A; Lee RW; Dick AD; Sallam A
Am J Ophthalmol; 2014 Dec; 158(6):1136-1145.e5. PubMed ID: 25217856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
